MTP - MTP STOCK NEWS

Midatech Pharma (AIM:MTPH.L)(NASDAQ:MTP) reported its audited preliminary results for the year ending December 31, 2021, showcasing a net loss of £5.46 million, a reduction from £22.19 million the previous year. Gross revenue increased to £0.58 million from £0.34 million in 2020, driven by an uptick in customer revenue. The company successfully advanced drug delivery technologies, partnering with Janssen on multiple drug formulations, including a long-acting injectable. As of December 31, 2021, cash reserves totaled £10.06 million.

Midatech Pharma PLC (NASDAQ: MTP) has received a Notification Letter from NASDAQ, stating non-compliance with the minimum bid price of $1.00 due to a closing bid price below this threshold for 30 consecutive business days. The company has a 180-day Compliance Period until October 10, 2022, to regain compliance. If not met, it may receive an additional 180-day grace period or face potential delisting. The Notification does not affect operations or AIM Market compliance. The company will monitor its share price and take necessary actions for compliance.

Midatech Pharma PLC has extended its R&D collaboration with Janssen Pharmaceutica NV, initially announced on July 21, 2020. The extension focuses on another undisclosed large molecule, leveraging Midatech's Q-Sphera technology to enhance drug loading and optimize in vitro release duration. This follows their success with the MTX213 molecule, where the Q-Sphera technology safely encapsulated a large molecule medicine while maintaining its functionality. Midatech's innovative drug delivery technologies are patented and have entered clinical use, highlighting their potential impact on patient care.

Midatech Pharma PLC has appointed Strand Hanson Limited as its Nominated and Financial Adviser, effective immediately. Turner Pope Investments will act as the sole broker for the company. Midatech focuses on improving drug delivery technology with several proprietary platforms aimed at enhancing the bio-delivery and biodistribution of medicines. The company holds significant intellectual property with 36 patent families and successful clinical applications, which position it for future growth.

Midatech Pharma PLC (AIM:MTPH)(NASDAQ:MTP) announced that its Investigational New Drug (IND) application for a Phase 1 study of MTX110 in patients with recurrent glioblastoma multiforme (rGBM) has been cleared by the US FDA. This study, utilizing MidaSolve™ technology for the direct delivery of the drug to tumors, aims to assess safety and tolerability. Recruitment is set to begin in the first half of 2022, targeting a significant medical need as GBM presents a low survival rate with current treatments.

Midatech Pharma PLC (AIM:MTPH, Nasdaq:MTP) announced it will release interim results for the six months ended 30 June 2021 on 17 September 2021 at 7.00 am BST. A webinar for shareholders will follow on 20 September 2021 at 5.30 pm BST, allowing participants to submit questions. Midatech focuses on drug delivery technology with proprietary platforms like Q-Sphera™, MidaSolve™, and MidaCore™, supported by 36 patent families. The company aims to enhance the bio-delivery of medicines, impacting patient lives significantly.

Midatech Pharma PLC has announced the appointment of Dr. Dmitry Zamoryakhin as the new Chief Scientific Officer, effective immediately. Dr. Zamoryakhin brings extensive experience from his previous roles, including Chief Medical Officer at Oxford Biomedica. He will replace Steve Damment, who is set to retire after six years with the company. CEO Stephen Stamp expressed confidence in Dr. Zamoryakhin's ability to drive the company's Q-Sphera programs and MTX110 forward towards partnership opportunities. Midatech focuses on innovative drug delivery technologies to enhance the bio-delivery of medicines.

Midatech Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP) reported breakthrough in vitro data showcasing its Q-Sphera technology's ability to formulate long-acting injectables for biologics. Over 13 months, the company pivoted from a singular focus on MTD201 to a diversified pipeline of nine earlier-stage programs, halving its cash burn. Significant milestones include successful mAb encapsulation, ongoing collaborations for MTX214 and MTX216, and advancements in MTD211 for long-acting brexpiprazole. The company also plans to initiate Phase II studies for MTX110 in brain cancers.

Midatech Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP) will host an investor webinar at 2.00pm BST / 9.00am EST on June 17, 2021, focusing on its R&D programs. This event is open to all shareholders and interested parties, with registration available through a provided link. Attendees can submit questions in advance or during the session. This initiative aims to enhance transparency and engagement with the investment community.